<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dostarlimab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dostarlimab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dostarlimab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="131464" href="/d/html/131464.html" rel="external">see "Dostarlimab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55732609"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Jemperli</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56746705"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Jemperli</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55717166"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-PD-1 Monoclonal Antibody;</li>
<li>
                        Antineoplastic Agent, Immune Checkpoint Inhibitor;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F55733350"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Select patients for treatment based on the presence of deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status in tumor specimens.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b275a35f-703f-43e4-9563-b5ef7382898b">Endometrial cancer, primary advanced or recurrent, dMMR or MSI-H, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer, primary advanced or recurrent, dMMR or MSI-H, combination </b>
<b>therapy: IV: </b>500 mg once every 3 weeks (in combination with carboplatin and paclitaxel) for 6 cycles, followed by dostarlimab single-agent therapy of 1,000 mg once every 6 weeks (beginning on day 1 of cycle 7) until disease progression, unacceptable toxicity, or for up to 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36972026','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36972026','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48428628-357e-475a-85cc-60749ee08e39">Endometrial cancer, recurrent or advanced, dMMR, single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer, recurrent or advanced, dMMR, single-agent therapy: IV: </b>500 mg once every 3 weeks for 4 doses, followed by 1,000 mg once every 6 weeks for dose 5 and beyond (administer dose 5 beginning 3 weeks after dose 4) until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e86b3494-604b-4e29-987c-40c40777b410">Solid tumors, recurrent or advanced, dMMR, single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, recurrent or advanced, dMMR, single-agent therapy: IV: </b>500 mg once every 3 weeks for 4 doses, followed by 1,000 mg once every 6 weeks for dose 5 and beyond (administer dose 5 beginning 3 weeks after dose 4) until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55733352"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function <i>prior</i> to treatment initiation:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in dostarlimab pharmacokinetics were observed in patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney toxicity <i>during</i> treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated nephritis with kidney dysfunction:</i> If dostarlimab treatment interruption or discontinuation is required, administer systemic corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or grade 3 serum creatinine elevation: Withhold dostarlimab; resume dostarlimab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 serum creatinine elevation: Permanently discontinue dostarlimab.</p></div>
<div class="block doha drugH1Div" id="F55733353"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment <i>prior</i> to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild (total bilirubin &gt;1 to 1.5 times ULN or AST &gt; ULN) or moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in dostarlimab pharmacokinetics were observed in patients with mild or moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity <i>during</i> treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If dostarlimab treatment interruption or discontinuation is required, administer systemic corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis </i>
<b>without</b>
<i> tumor involvement of the liver:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;3 up to 8 times ULN or total bilirubin &gt;1.5 up to 3 times ULN: Withhold dostarlimab treatment. Resume dostarlimab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;8 times ULN or total bilirubin &gt;3 times ULN: Permanently discontinue dostarlimab.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis </i>
<b>with </b>
<i>tumor involvement of the liver:</i>
<b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:8em;">If baseline AST or ALT &gt;1 up to 3 times ULN and increases to &gt;5 up to 10 times ULN or baseline AST or ALT &gt;3 up to 5 times ULN and increases to &gt;8 up to 10 times ULN: Withhold dostarlimab treatment. Resume dostarlimab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT increases to &gt;10 times ULN or total bilirubin increases to &gt;3 times ULN: Permanently discontinue dostarlimab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Additional</b>
<b> recommendations:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2 immune-mediated hepatitis:</i> Withhold immune checkpoint inhibitor (ICI); if no improvement within 3 to 5 days after ICI is withheld, consider initiation of corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4 immune-mediated hepatitis:</i> Withhold ICI; initiate corticosteroids (methylprednisolone 1 to 2 mg/kg or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with methylprednisolone 1 mg/kg/day demonstrated similar time to ALT normalization (compared with higher methylprednisolone doses), while reducing the potential for corticosteroid-related complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34709662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34709662'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F55733356"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> No dosage reductions of dostarlimab are recommended. Other concomitant combination therapy medications may also require treatment interruption, dosage reduction, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune-mediated adverse reactions (general information):</b> Withhold dostarlimab for severe (grade 3) immune-mediated adverse reactions. Permanently discontinue dostarlimab for life-threatening (grade 4) immune-mediated adverse reactions, recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or inability to reduce corticosteroid dose to prednisone ≤10 mg/day (or equivalent) within 12 weeks of initiating corticosteroids. If dostarlimab treatment interruption or discontinuation is required, administer systemic corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent]) until improvement to ≤ grade 1; upon improvement to ≤ grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with corticosteroid therapy. Systemic corticosteroids may not be necessary for certain adverse reactions. Hormone replacement therapy may be required for endocrinopathies (if clinically indicated). See table for additional dosage modification guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional management </i>
<i>recommendations:</i> Consider withholding checkpoint inhibitor therapy for most grade 2 toxicities and resume when symptoms and/or lab values resolve to ≤ grade 1; systemic corticosteroids (initial dose of 0.5 to 1 mg/kg/day prednisone [or equivalent]) may be administered if indicated for grade 2 toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Refer to guideline for further information regarding management of immune-mediated adverse reactions associated with checkpoint inhibitor therapy.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Dostarlimab Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Dostarlimab dosage modification</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; DRESS = drug rash with eosinophilia and systemic symptoms.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>b</sup> Refer to Prednisone monograph for tapering recommendations when used for immune-mediated adverse reactions associated with checkpoint inhibitor therapy.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Immune-mediated adverse reactions</i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Cardiovascular toxicity: Myocarditis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2, 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue dostarlimab.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;">Dermatologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Mild or moderate nonbullous/exfoliative rash</p></td>
<td align="center">
<p style="text-indent:0em;">May be managed with topical emollients and/or topical corticosteroids.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Exfoliative dermatologic conditions: Suspected SJS, TEN, or DRESS<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Withhold dostarlimab; resume dostarlimab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper<sup>b</sup>. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Confirmed SJS, TEN, or DRESS<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue dostarlimab.</p></td></tr>
<tr>
<td align="left" rowspan="6">
<p style="text-indent:0em;">Endocrinopathies</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2, 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold dostarlimab until clinically stable or permanently discontinue depending on severity. If withheld, resume dostarlimab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Adrenal insufficiency, ≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate symptomatic management (including hormone replacement as clinically indicated).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Diabetes, type 1</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate insulin as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypophysitis</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hyperthyroidism</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypothyroidism</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate thyroid hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">GI toxicity: Colitis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2 or 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold dostarlimab; resume dostarlimab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper<sup>b</sup>. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue dostarlimab.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Neurologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold dostarlimab; resume dostarlimab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper<sup>b</sup>. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue dostarlimab.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Ocular disorders: Vogt-Koyanagi-Harada-like syndrome</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">May require systemic corticosteroids to reduce the risk of permanent vision loss.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Pulmonary toxicity: Pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold dostarlimab; resume dostarlimab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper<sup>b</sup>. Permanently discontinue dostarlimab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4 or recurrent grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue dostarlimab.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Other adverse reactions</i></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Infusion reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt or slow the rate of dostarlimab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue dostarlimab.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F55733351"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F55724437"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (15% to 19%), skin rash (14% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (26% to 36%), decreased serum magnesium (16% to 28%), decreased serum potassium (14% to 22%), decreased serum sodium (21% to 29%), hypothyroidism (8% to 11%), increased serum potassium (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (16% to 23%), decreased appetite (12% to 15%), diarrhea (25% to 29%; grades 3/4: 2% to 3%), nausea (22% to 32%; grades 3/4: &lt;1%), vomiting (17% to 23%; grades 3/4: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (30% to 35%; grades 3/4: 11% to 18%), decreased neutrophils (12% to 17%; grades 3/4: 2% to 3%), leukopenia (18% to 21%; grades 3/4: 1% to 2%), lymphocytopenia (33% to 46%; grades 3/4: 7% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (22% to 25%), increased serum alkaline phosphatase (26% to 31%), increased serum aspartate aminotransferase (26% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (42% to 49%; including asthenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (21% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (13% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (12% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (1%), decreased serum calcium (3%), hypermagnesemia (4%), hyperthyroidism (2%), increased serum calcium (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (1%), enterocolitis (&lt;10%), gastritis (&lt;10%), hemorrhagic colitis (&lt;10%), pancreatitis (including acute pancreatitis: &lt;10%), severe abdominal pain (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (&lt;10%), increased serum bilirubin (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (including severe infusion-related reaction: &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2%; neutralizing: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (&lt;10%), encephalitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (&lt;10%), myalgia (10%), myositis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iridocyclitis (&lt;10%), uveitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease (&lt;10%), pneumonitis (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis, pericarditis, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoparathyroidism, hypophysitis, thyroiditis, type 1 diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Duodenitis, increased serum amylase, increased serum lipase</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, autoimmune hemolytic anemia, hemophagocytic lymphohistiocytosis, immune thrombocytopenia, lymphadenitis (histiocytic necrotizing lymphadenitis [Kikuchi lymphadenitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Organ transplant rejection (solid), sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Systemic inflammatory response syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Demyelinating disease, Guillain-Barré syndrome, meningitis, myasthenia (myasthenic syndrome), myasthenia gravis, neuropathy (autoimmune), paresis (nerve)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myelitis, polymyalgia rheumatica, polymyositis, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephritis (including interstitial nephritis)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (SITC [Brahmer 2021]), toxic epidermal necrolysis (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis (SITC [Brahmer 2021]), cholecystitis (SITC [Brahmer 2021]), esophagitis (SITC [Brahmer 2021]), xerostomia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (SITC [Brahmer 2021]), pure red cell aplasia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sjögren disease (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome (SITC [Brahmer 2021])</p></div>
<div class="block coi drugH1Div" id="F55717137"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to dostarlimab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55733339"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse reactions (immune-mediated): Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockers (including dostarlimab) remove immune response inhibition, thus potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Severe and fatal immune-mediated adverse reactions may occur in any organ system or tissue. Reactions generally occur during treatment (may occur at any time after dostarlimab initiation); reactions may also occur after dostarlimab discontinuation. Early identification and management of immune-mediated adverse reactions are necessary to ensure safe use of dostarlimab. If suspected immune-mediated reactions occur, initiate appropriate workup to exclude alternative causes (including infection). Medically manage immune-mediated adverse reactions promptly and refer for specialty consultation as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Immune-mediated rash or dermatitis may occur. Bullous and exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN) have occurred with anti-PD-1/PD-L1 monoclonal antibodies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endocrinopathies: Dostarlimab is associated with immune-mediated endocrinopathies.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Adrenal insufficiency</i>: Primary and secondary adrenal insufficiency have occurred, including cases of grade 2 or 3 adrenal insufficiency; systemic corticosteroids were required in some patients. In cases where dostarlimab was withheld for adrenal insufficiency, all reinitiated treatment after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Diabetes mellitus</i>: Type 1 diabetes mellitus may occur (which may present with diabetic ketoacidosis). Diabetes did not result in permanent dostarlimab discontinuation, although events did not resolve and some patients required long-term insulin therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Hypophysitis:</i> Immune-mediated hypophysitis may occur and present with acute mass effect symptoms (headache, photophobia, or visual field defects). Grade 2 hypophysitis was observed (with single-agent dostarlimab; grade 3 hypophysitis was observed when dostarlimab was administered in combination with chemotherapy). Systemic corticosteroids were required and hypophysitis resolved in some cases but did not resolve in other cases. Hypophysitis may lead to hypopituitarism.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Thyroid disorders:</i> Immune-mediated thyroid disorders may occur. Hyperthyroidism occurred in a small percentage of patients, including grade 2 and 3 events (some required antithyroid therapy or systemic corticosteroids). Hypothyroidism has occurred, all of which were grade 2 (most requiring thyroid hormone replacement therapy and some cases requiring discontinuation). Hypothyroidism may follow hyperthyroidism. Thyroiditis occurred rarely (grade 2) and did not result in permanent discontinuation, although events did not resolve; systemic corticosteroids and antithyroid therapy were administered to some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Immune-mediated colitis has occurred, including cases of grade 2 and 3 colitis. Systemic corticosteroids were administered to most patients for immune-mediated colitis. The majority of patients with colitis experienced resolution of symptoms. In cases where dostarlimab was withheld for colitis, all reinitiated treatment after symptom improvement; recurrence occurred in one patient. Cytomegalovirus infection or reactivation has been observed in patients with corticosteroid-refractory, immune-mediated colitis. Pancreatitis (including increased serum amylase and lipase levels), gastritis, and duodenitis have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Immune-mediated hepatitis (grade 3) has occurred with dostarlimab. Systemic corticosteroids were used in most patients to manage immune-mediated hepatitis; hepatitis resolved in most patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions (including severe and life-threatening cases) have occurred with anti-PD-1/PD-L1 monoclonal antibodies; a grade 3 severe infusion-related reaction has been reported with dostarlimab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Immune-mediated nephritis (including tubulointerstitial nephritis) with kidney dysfunction has occurred, all of which were grade 2. Systemic corticosteroids may be required. Nephritis resolved in most affected patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Immune-mediated uveitis, iritis, and other ocular inflammatory toxicities may occur. Some cases can be associated with retinal detachment. Differing grades of visual impairment (including blindness) may occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Immune-mediated pneumonitis has been observed, including grades 2 to 4 cases. Most patients required management with systemic corticosteroids. Pneumonitis resolved in nearly 80% of the affected patients. In cases where dostarlimab was withheld for pneumonitis, some reinitiated dostarlimab after symptom improvement; pneumonitis recurred in some patients. Pneumonitis incidence may be increased in patients with a history of prior thoracic radiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Other immune-mediated toxicities: Other clinically relevant immune-mediated disorders have been observed rarely with dostarlimab (or other anti-PD-1/PD-L1 monoclonal antibodies) and may affect any organ system (may be fatal), including myocarditis, pericarditis, vasculitis, meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy, myositis/polymyositis, rhabdomyolysis (and associated sequelae including kidney failure), arthritis, polymyalgia rheumatic, hypoparathyroidism, autoimmune hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, and solid organ transplant rejection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematopoietic cell transplant: Fatal and other serious complications may occur in patients who receive allogeneic hematopoietic cell transplant (HCT) before or after treatment with an anti-PD-L1/PD-1 monoclonal antibody. Transplant-related complications included hyperacute graft-versus-host disease (GVHD), acute or chronic GVHD, hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome) after reduced-intensity conditioning, and steroid-requiring febrile syndrome (with no identified infectious etiology). These complications may occur despite intervening therapy between PD-L1/PD-1 blockade and HCT. Manage early signs/symptoms of transplant-related complications promptly. Assess the risks/benefits of treatment with an anti-PD-L1/PD-1 monoclonal antibody prior to or after an allogenic HCT.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Checkpoint inhibitors may worsen or precipitate new myasthenia gravis (MG), especially within the first 16 weeks of treatment; use with caution. Patients with well-controlled MG may be considered for checkpoint inhibitor therapy if MG treatment is maintained (or reinitiated in patients whose MG is in remission), combination therapy (eg, anti-CTLA-4 with anti-PD-a/PD-L1 monoclonal antibodies) is avoided, and respiratory and bulbar function are closely followed. In patients who develop overt MG during checkpoint inhibitor therapy, early aggressive treatment with plasma exchange or IVIg in combination with high-dose corticosteroids may be required (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<i>
<b>Dosage form specific issues</b></i>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and kidney and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for single-agent treatment of recurrent or advanced endometrial cancer or solid tumors based on the presence of deficient mismatch repair (dMMR) in tumor specimens. Select patients for combination therapy treatment of primary advanced or recurrent endometrial cancer based on dMMR or microsatellite instability-high (MSI-H) status in tumor specimens. Information on approved tests may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=8RYIFfyLhIBYEqeX7m6uPL%2BISq6mLQ5ujNO7kK81dq2dNX8kElyjyAULgMalHjogrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=131441" target="_blank">https://www.fda.gov/companiondiagnostics</a>. The effect of prior chemotherapy on dMMR test results in high-grade glioma is unclear; in patients with high-grade gliomas, it is recommended to test for dMMR in the primary tumor specimen (obtained prior to temozolomide initiation).</p></div>
<div class="block foc drugH1Div" id="F55732610"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jemperli: Dostarlimab-gxly 500 mg/10 mL (10 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F55732608"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55830455"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Jemperli Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/10 mL (per mL): $1,360.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56746706"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jemperli: Dostarlimab-gxly 500 mg/10 mL (10 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F55733357"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 30 minutes through a 0.2 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. IV tubing should be made of PVC or platinum-cured silicon and fittings should be made of PVC or polycarbonate. Do not administer as an IV push or bolus. Do not infuse other medications through the same infusion line.</p>
<p style="text-indent:-2em;margin-left:4em;">Interrupt or slow the infusion for grade 1 or 2 infusion-related reactions; permanently discontinue for grade 3 or 4 infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Combination therapy for primary advanced or recurrent endometrial cancer: Administer dostarlimab first, followed by carboplatin and paclitaxel when administered on the same day.</p></div>
<div class="block meg drugH1Div" id="F55748068"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761174s006lbl.pdf%23page%3D34&amp;token=8yFm29GVPLk%2B%2Bup7dd2nIhe4qa8X%2FQY6rugeLl%2FW82WRnxlCaqmhrUh5gdN%2Fe%2B28%2FByoP50dUC8Neu9%2Frn%2Fbui%2BIBNjLKRlWmbnv8dAahTKhTSxA9iN7UXzVUI1IuZAo&amp;TOPIC_ID=131441" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf#page=34</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F55717136"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer, recurrent or advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab) of primary advanced or recurrent endometrial cancer in adults that is mismatch repair deficient (dMMR) (as determined by an approved test) or microsatellite instability-high (MSI-H).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (single agent) of dMMR recurrent or advanced endometrial cancer in adults (as determined by an approved test) that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, recurrent or advanced: </b>Treatment (single agent) of dMMR recurrent or advanced solid tumors in adults (as determined by an approved test) that has progressed on or following prior treatment and who have no satisfactory alternative treatment options.</p></div>
<div class="block mst drugH1Div" id="F55733326"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dostarlimab may be confused with atezolizumab, cemiplimab, daratumumab, dinutuximab, durvalumab, ipilimumab, nivolumab, pembrolizumab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55742183"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55742180"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies) may enhance the hepatotoxic effect of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55733336"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 4 months after the last dose of dostarlimab.</p></div>
<div class="block pri drugH1Div" id="F55733337"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dostarlimab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, in utero exposure to dostarlimab may lead to an immune-mediated rejection of the fetus, resulting in fetal death.</p></div>
<div class="block brc drugH1Div" id="F55733338"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dostarlimab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Dostarlimab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 4 months after the last dostarlimab dose.</p></div>
<div class="block mop drugH1Div" id="F55733359"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Mismatch repair deficient (dMMR) status (in tumor specimens) in dMMR advanced or recurrent endometrial cancer or solid tumors. For primary advanced or recurrent endometrial cancer, assess dMMR or microsatellite instability-high (MSI-H) status in tumor specimens. In high-grade glioma, test for dMMR in the primary tumor specimen (obtained prior to temozolomide initiation). Monitor LFTs (AST, ALT, and total bilirubin; at baseline and periodically during treatment); kidney function (serum creatinine; at baseline and periodically during treatment); thyroid function (at baseline, periodically during treatment, and as clinically indicated); monitor blood glucose (for hyperglycemia). Verify pregnancy status prior to therapy initiation (in patients who can become pregnant). Monitor closely for signs/symptoms of immune-mediated adverse reactions, including adrenal insufficiency, diarrhea/colitis (consider initiating or repeating infectious workup in patients with corticosteroid-refractory, immune-mediated colitis to exclude alternative causes), dermatologic toxicity, diabetes mellitus, hypophysitis, ocular disorders, thyroid disorders, pneumonitis, and other immune-mediated adverse reactions. Monitor for signs/symptoms of infusion-related reactions. If received/receiving hematopoietic stem cell transplant, monitor closely for early signs/symptoms of transplant-related complications.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Obtain baseline ECG, natriuretic peptides, and troponins in all patients; obtain a baseline echocardiogram in high-risk patients; consider serial ECGs and cardiac troponins prior to doses 2, 3, and 4, and if normal, reduce to every 3 doses until completion of therapy; cardiovascular risk assessment every 6 to 12 months in high-risk patients who require long-term therapy (&gt;12 months therapy, consider cardiovascular risk assessment every 6 to 12 months in all patients requiring long-term therapy) (ESC [Lyon 2022]). Refer to a cardiologist when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional suggested monitoring (ASCO [Schneider 2021]): Prior to therapy: CBC with differential, serum chemistries, creatine kinase, comprehensive clinical assessment including performance status, weight, BMI, heart rate, BP, and oxygen saturation; consider chest x-ray, electrocardiogram, and CT scan; assess history of autoimmune conditions, organ-specific disease, endocrinopathies, neuropathy, and infectious disease; assess bowel habits, respiratory symptoms, skin (for rash), arthralgias, and neurologic symptoms. During therapy: Assess BP, weight, heart rate, and oxygen saturation; assess for infections, screen for hyperglycemia/diabetes (polyuria, polydipsia, weight loss); eye exam (including intraocular pressure after 6 weeks), CBC with differential, serum chemistries, and creatine kinase; monitor bone mineral density (with long-term therapy).</p></div>
<div class="block pha drugH1Div" id="F55733344"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dostarlimab is an anti-PD-1 humanized IgG4 monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding. Blocking the PD-1 pathway inhibits the negative immune regulation caused by PD-1 receptor signaling (Hamid 2013).</p></div>
<div class="block phk drugH1Div" id="F55733345"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~5.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Expected to be metabolized by catabolic pathways into small peptides and amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 23.5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 0.007 L/hour (at steady state).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522338"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Jemperli</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23724846">
<a name="23724846"></a>Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>N Engl J Med</i>. 2013;369(2):134-144. doi:10.1056/NEJMoa1305133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/23724846/pubmed" id="23724846" target="_blank">23724846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jemperli (dostarlimab-gxly) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline LLC; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jemperli.2">
<a name="Jemperli.2"></a>Jemperli (dostarlimab) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36972026">
<a name="36972026"></a>Mirza MR, Chase DM, Slomovitz BM, et al; RUBY Investigators. Dostarlimab for primary advanced or recurrent endometrial cancer. <i>N Engl J Med</i>. 2023;388(23):2145-2158. doi:10.1056/NEJMoa2216334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/36972026/pubmed" id="36972026" target="_blank">36972026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33001143">
<a name="33001143"></a>Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. <i>JAMA Oncol</i>. 2020;6(11):1766-1772. doi:10.1001/jamaoncol.2020.4515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/33001143/pubmed" id="33001143" target="_blank">33001143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dostarlimab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131441 Version 68.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
